Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 6:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 222 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Test Vaccine Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children

NCT00764790
View directory record Official record
Conditions
Influenza
Interventions
Fluarix, Fluzone
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 35 Months
Enrollment
3,317 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
62
States / cities
Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Sep 8, 2026, 6:59 PM EDT
Recruiting No phase listed Observational

Real-World Effectiveness of Perinatal RSV Immunoprophylaxis

NCT06172660
View directory record Official record
Conditions
RSV Infection
Interventions
Nirsevimab
Drug
Lead sponsor
Yale University
Other
Eligibility
Up to 12 Months
Enrollment
3,750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Sep 8, 2026, 6:59 PM EDT
Not listed Not applicable Interventional

Increasing HPV Immunization Rates: The Rural Adolescent Vaccine Enterprise

NCT03604393
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Practice facilitation
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 89 Years
Enrollment
22,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 8, 2026, 6:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines

NCT02415842
View directory record Official record
Conditions
Immunologic Tests
Interventions
Serum samples
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 64 Years
Enrollment
414 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 8, 2026, 6:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older

NCT00753272
View directory record Official record
Conditions
Influenza
Interventions
GSK Bio's influenza vaccine GSK2186877A, Fluarix TM
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years and older
Enrollment
43,695 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
63
States / cities
Alabaster, Alabama • Huntsville, Alabama • Mobile, Alabama + 51 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Sep 8, 2026, 6:59 PM EDT
Completed Phase 3 Interventional

Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment

NCT05894954
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia, Mild
Interventions
Precision Medicine Approach, Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises, Standard-of-Care, Lifestyle including diet, exercise, stress management
Dietary Supplement · Combination Product · Behavioral
Lead sponsor
Alzheimer's Prevention and Reversal Project, Inc.
Other
Eligibility
45 Years to 76 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Folsom, California • San Rafael, California • Walnut Creek, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 8, 2026, 6:59 PM EDT
Completed Phase 1 Interventional

HIV-1 Vaccine Test in Uninfected Adult Volunteers

NCT00047931
View directory record Official record
Conditions
HIV Seronegativity, AIDS Vaccines
Interventions
VRC-HIVDNA009-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 8, 2026, 6:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents

NCT01424644
View directory record Official record
Conditions
Meningococcal Meningitis
Interventions
Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine, MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
Biological
Lead sponsor
Novartis
Industry
Eligibility
11 Years to 18 Years
Enrollment
801 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
17
States / cities
Birmingham, Alabama • Fremont, California • Madera, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Sep 8, 2026, 6:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies

NCT02151448
View directory record Official record
Conditions
Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma, Peritoneal Carcinomatosis
Interventions
DC vaccine, Celecoxib, Interferon Alfa-2b, rintatolimod
Biological · Drug
Lead sponsor
David Bartlett
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 19, 2020 · Synced Sep 8, 2026, 6:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prediction and Testing of Antigenic Sites of the AIDS Virus, HTLV-III Recognized by T Lymphocytes for the Development of Synthetic Vaccines

NCT00001210
View directory record Official record
Conditions
HIV Infections, Healthy
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1986 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 8, 2026, 6:59 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Trial in HPV Prevention for the U.S. Vietnamese Community

NCT07637630
View directory record Official record
Conditions
HPV-related Cancers, HPV Vaccination
Interventions
Expert Video, Self-persuasion, Narrative Storytelling, Motivational Interviewing, Constant Component
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 8, 2026, 6:59 PM EDT
Enrolling by invitation Phase 4 Interventional

Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients

NCT06162494
View directory record Official record
Conditions
Varicella Zoster
Interventions
Recombinant Zoster Vaccine
Biological
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
19 Years to 40 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 8, 2026, 6:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Systems Biology of Flu Vaccine in Healthy Adults With and Without the Use of Antibiotics

NCT02154061
View directory record Official record
Conditions
Influenza
Interventions
IIV Flu Vaccine, Metronidazole, Neomycin, Vancomycin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 40 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Sep 8, 2026, 6:59 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

NCT05685004
View directory record Official record
Conditions
Glioblastoma Multiforme of Brain
Interventions
TVI-Brain-1, Standard of Care, Radiotherapy, Temozolomide
Biological · Procedure · Radiation + 1 more
Lead sponsor
TVAX Biomedical
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Tucson, Arizona • Los Angeles, California • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Sep 8, 2026, 6:59 PM EDT
Completed Phase 3 Interventional Results available

Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects

NCT00937950
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
Gynaecological follow-up
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
2,022 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
18
States / cities
Clearwater, Florida • Miami, Florida • Honolulu, Hawaii + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Sep 8, 2026, 6:59 PM EDT
Active, not recruiting Not applicable Interventional

Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study

NCT05065840
View directory record Official record
Conditions
Human Papilloma Virus, Human Papilloma Virus Vaccine
Interventions
CDC 4 Pillars Program
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 45 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Albany, Georgia • Atlanta, Georgia • Lithonia, Georgia
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 8, 2026, 6:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks

NCT03954743
View directory record Official record
Conditions
Infections, Rotavirus
Interventions
PCV-free liquid formulation of GSK's oral live attenuated HRV vaccine, Lyophilized formulation of GSK's oral live attenuated HRV vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,351 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
19
States / cities
Birmingham, Alabama • Colorado Springs, Colorado • Louisville, Kentucky + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Sep 8, 2026, 6:59 PM EDT
Completed Phase 1 Interventional

Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects

NCT00623259
View directory record Official record
Conditions
HIV Infections
Interventions
MVA-mBN120B
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 19, 2010 · Synced Sep 8, 2026, 6:59 PM EDT
Terminated Phase 3 Interventional Results available

Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients

NCT05220397
View directory record Official record
Conditions
Kidney Transplant Recipient
Interventions
Janssen Ad26.CoV2.S Vaccine, Reduction in Immunosuppression Medication, Maintenance in Immunosuppression Medication
Biological · Other
Lead sponsor
Mark Stegall
Other
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 8, 2026, 6:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers

NCT02891980
View directory record Official record
Conditions
Ebola Disease, Marburg Disease
Interventions
Ad26 Zaire Ebola Vaccine, MVA Multi-Filo Ebola Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Sep 8, 2026, 6:59 PM EDT
Recruiting Phase 1 Interventional

Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer

NCT07652242
View directory record Official record
Conditions
Triple Negative Breast Cancer (TNBC)
Interventions
ITI-5000 mRNA Vaccine, Pembrolizumab, Olaparib, Capecitabine, ITI-5000 MTD (Maximum Tolerated Dose)
Biological · Drug
Lead sponsor
Immunomic Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Grand Rapids, Michigan • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 8, 2026, 6:59 PM EDT
Completed Not applicable Interventional

Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2

NCT00363012
View directory record Official record
Conditions
Breast Cancer
Interventions
HER-2/neu intracellular domain protein, flow cytometry, immunohistochemistry staining method, biopsy, Sterile water placement
Biological · Other · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Sep 8, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Serologic Assay Validation and Proficiency Testing of HIL-214 in Adults

NCT05972733
View directory record Official record
Conditions
Gastroenteritis
Interventions
HIL-214
Biological
Lead sponsor
HilleVax
Industry
Eligibility
18 Years to 49 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Rolling Hills Estates, California • Stockbridge, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Sep 8, 2026, 6:59 PM EDT
Completed Not applicable Interventional

Education Intervention on Vaccination Adherence Among Inflammatory Bowel Disease (IBD) Patients

NCT04672161
View directory record Official record
Conditions
Crohn Disease (CD), Ulcerative Colitis (UC), Indeterminate Colitis
Interventions
Vaccine Education
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 8, 2026, 6:59 PM EDT